Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans.

T cell-mediated heterologous immunity to different pathogens is promising for the development of immunotherapeutic strategies. Aspergillus fumigatus and Candida albicans, the 2 most common fungal pathogens causing severe infections in immunocompromised patients, are controlled by CD4+ type 1 helper T (T(H)1) cells in humans and mice, making induction of fungus-specific CD4+ T(H)1 immunity an appealing strategy for antifungal therapy. We identified an immunogenic epitope of the A fumigatus cell wall glucanase Crf1 that can be presented by 3 common major histocompatibility complex class II alleles and that induces memory CD4+ T(H)1 cells with a diverse T-cell receptor repertoire that is cross-reactive to C albicans. In BALB/c mice, the Crf1 protein also elicits cross-protection against lethal infection with C albicans that is mediated by the same epitope as in humans. These data illustrate the existence of T cell-based cross-protection for the 2 distantly related clinically relevant fungal pathogens that may foster the development of immunotherapeutic strategies.

[1]  J. Latgé,et al.  Cross-Reactive TH1 Cells to Aspergillus Fumigatus and Candida Albicans , 2010 .

[2]  S. Green,et al.  Altered effector functions of virus‐specific and virus cross‐reactive CD8+ T cells in mice immunized with related flaviviruses , 2010, European journal of immunology.

[3]  J. Staab,et al.  Healthy Human T-Cell Responses to Aspergillus fumigatus Antigens , 2010, PloS one.

[4]  Hao Liu,et al.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. , 2010, Blood.

[5]  S. Dalai,et al.  Suboptimal engagement of the T‐cell receptor by a variety of peptide–MHC ligands triggers T‐cell anergy , 2010, Immunology.

[6]  H. Einsele,et al.  Identification of Low Frequency Multiple Novel Aspergillus Fumigatus Specific MHC Class II Epitopes and Rapid Generation of An Aspergillus -Specific T-Cell Product Based On Activation Dependent Expression of CD154. , 2009 .

[7]  Katia Perruccio,et al.  Surface hydrophobin prevents immune recognition of airborne fungal spores , 2009, Nature.

[8]  A. Beauvais,et al.  Immune Sensing of Aspergillus Fumigatus Proteins, Glycolipids, and Polysaccharides and the Impact on Th Immunity and Vaccination 1 Materials and Methods A. Fumigatus Strain and Infection the Journal of Immunology , 2009 .

[9]  J. Latgé,et al.  Immune Responses of Human Immature Dendritic Cells Can Be Modulated by the Recombinant Aspergillus fumigatus Antigen Aspf1 , 2009, Clinical and Vaccine Immunology.

[10]  P. Puccetti,et al.  Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans , 2009, Mucosal Immunology.

[11]  D. Stevens,et al.  Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. , 2009, Vaccine.

[12]  A. Becker,et al.  CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. , 2009, Brain : a journal of neurology.

[13]  Francisco A. Chaves,et al.  Infection of HLA-DR1 Transgenic Mice with a Human Isolate of Influenza A Virus (H1N1) Primes a Diverse CD4 T-Cell Repertoire That Includes CD4 T Cells with Heterosubtypic Cross-Reactivity to Avian (H5N1) Influenza Virus , 2009, Journal of Virology.

[14]  A. Barrett,et al.  Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. , 2009, Vaccine.

[15]  K. Marr.  Fungal infections in hematopoietic stem cell transplant recipients. , 2008, Medical mycology.

[16]  L. Lombardelli,et al.  T cells specific for Candida albicans antigens and producing type 2 cytokines in lesional mucosa of untreated HIV-infected patients with pseudomembranous oropharyngeal candidiasis. , 2008, Microbes and infection.

[17]  D. Margolis,et al.  Stimulation by means of dendritic cells followed by Epstein–Barr virus‐transformed B cells as antigen‐presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16‐specific cytotoxic T cell responses , 2007, Clinical and experimental immunology.

[18]  Bernard Malissen,et al.  What guides MHC-restricted TCR recognition? , 2007, Seminars in immunology.

[19]  J. Latgé,et al.  The GPI‐anchored Gas and Crh families are fungal antigens , 2007, Yeast.

[20]  Francisco A. Chaves,et al.  The impact of DM on MHC class II–restricted antigen presentation can be altered by manipulation of MHC–peptide kinetic stability , 2006, The Journal of experimental medicine.

[21]  D. Underhill,et al.  Dectin-1 and TLRs Permit Macrophages to Distinguish between Different Aspergillus fumigatus Cellular States1 , 2006, The Journal of Immunology.

[22]  J. Latgé,et al.  Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. , 2006, Blood.

[23]  A. Tosti,et al.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. , 2005, Blood.

[24]  R. Rappuoli,et al.  A novel glyco-conjugate vaccine against fungal pathogens , 2005, The Journal of experimental medicine.

[25]  F. Brasseur,et al.  Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines , 2005, Gene Therapy.

[26]  T. Walsh,et al.  Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. , 2005, Medical mycology.

[27]  L. Romani.  Immunity to fungal infections , 2004, Nature Reviews Immunology.

[28]  G. Rasi,et al.  Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. , 2004, Blood.

[29]  H. Einsele,et al.  Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. , 2004, Blood.

[30]  J. Latgé,et al.  Aspergillus fumigatus antigens activate innate immune cells via toll‐like receptors 2 and 4 , 2004, British journal of haematology.

[31]  G. Pawelec.  Extrathymic T-cell differentiation in vitro , 2004, Nature Reviews Immunology.

[32]  J. Latgé,et al.  Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. , 2002, Blood.

[33]  D. Pietrella,et al.  Mannoprotein from Cryptococcus neoformans Promotes T-Helper Type 1 Anticandidal Responses in Mice , 2002, Infection and Immunity.

[34]  S. Riddell,et al.  Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. , 2002, Blood.

[35]  V. Kurup,et al.  Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. , 2002, Microbes and infection.

[36]  Raymond M. Welsh,et al.  No one is naive: the significance of heterologous T-cell immunity , 2002, Nature Reviews Immunology.

[37]  C. Montagnoli,et al.  Dendritic Cells Transport Conidia and Hyphae of Aspergillus fumigatus from the Airways to the Draining Lymph Nodes and Initiate Disparate Th Responses to the Fungus1 , 2002, The Journal of Immunology.

[38]  M. Martelli,et al.  Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. , 2001, Blood.

[39]  Thierry Fontaine,et al.  Glycosylphosphatidylinositol-anchored Glucanosyltransferases Play an Active Role in the Biosynthesis of the Fungal Cell Wall* , 2000, The Journal of Biological Chemistry.

[40]  U. Reichard,et al.  Molecular cloning and targeted deletion of PEP2 which encodes a novel aspartic proteinase from Aspergillus fumigatus. , 2000, International journal of medical microbiology : IJMM.

[41]  R. Hay,et al.  Production and Characterization of RecombinantAspergillus fumigatus Cu,Zn Superoxide Dismutase and Its Recognition by Immune Human Sera , 2000, Journal of Clinical Microbiology.

[42]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[43]  J. Latgé,et al.  Aspergillus fumigatus and Aspergillosis , 1999, Clinical Microbiology Reviews.

[44]  D. Mason,et al.  A very high level of crossreactivity is an essential feature of the T-cell receptor. , 1998, Immunology today.

[45]  J. Shea,et al.  Probing the active site of mitogillin, a fungal ribotoxin , 1998, Molecular microbiology.

[46]  J. Nemunaitis,et al.  Use of macrophage colony-stimulating factor in the treatment of fungal infections. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  J. Latgé,et al.  Cloning and disruption of the antigenic catalase gene of Aspergillus fumigatus , 1997, Infection and immunity.

[48]  A. Mccarthy.  Development , 1996, Current Opinion in Neurobiology.

[49]  N. Shastri,et al.  Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Uhlig,et al.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon , 1993, Infection and immunity.

[51]  P. Charmley,et al.  The extent of the human germline T-cell receptor V beta gene segment repertoire , 2004, Immunogenetics.

[52]  M. Oudshoorn,et al.  Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. , 1996, Human immunology.

[53]  P. Gregersen,et al.  Oligoclonality of CD8+ T cells in multiple sclerosis. , 1996, Autoimmunity.